Prelude Capital Management’s Cytek Biosciences CTKB Stock Holding History

Prelude Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57.7K	Sell	13,200 -200	-1%	-$944	﹤0.01%	1118
2025 Q4	$67.7K	Buy	+13,400	New	+$62.2K	0.01%	1219
2025 Q2	–	Sell	-19,200	Closed	-$77K	–	1063
2025 Q1	$77K	Sell	19,200 -9,680	-34%	-$50.2K	0.01%	1062
2024 Q4	$187K	Sell	28,880 -7,004	-20%	-$41.7K	0.01%	1013
2024 Q3	$199K	Buy	35,884 +18,970	+112%	+$108K	0.01%	1074
2024 Q2	$94.4K	Buy	16,914 +1,114	+7%	+$6.69K	0.01%	1104
2024 Q1	$106K	Buy	+15,800	New	+$125K	0.01%	1195
2023 Q2	–	Sell	-18,172	Closed	-$167K	–	1169
2023 Q1	$167K	Buy	+18,172	New	+$195K	0.01%	891

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prelude Capital Management's CTKB Position: Q1 2026 in Review

Prelude Capital Management reduced its Cytek Biosciences (CTKB) stake by 1.5% in Q1 2026, selling an estimated $944 and leaving 13,200 shares worth $57.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1118.

Prelude Capital Management first reported a position in CTKB in Q1 2023 and has held it in 8 quarters since. The position peaked at $199K in Q3 2024. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

Prelude Capital Management held 13,200 shares of Cytek Biosciences worth $57.7K as of Q1 2026.
Prelude Capital Management sold 200 Cytek Biosciences shares in Q1 2026, an estimated $944.
Cytek Biosciences made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1118 holding.
Prelude Capital Management first reported a position in Cytek Biosciences in Q1 2023 and has held it in 8 quarters since.
Prelude Capital Management's Cytek Biosciences position peaked at $199K in Q3 2024.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.